DGAP-News

Press Release: 4SC announces financial results for the first nine months and the third quarter of 2014 - Seite 2

interim results from the two Phase I/II trials in Asia in the indications
of liver cancer and non-small-cell lung cancer that are being conducted by
Yakult Honsha and the start of the randomised Phase II part of both trials
demonstrate the strong commitment of our partner Yakult and strengthen our
dedication to pushing forward with our further clinical development of
resminostat, especially in the indication of liver cancer."

Enno Spillner continued: "Also underpinning our positive attitude is the
work of 4SC Discovery. Together with its collaboration partner CRELUX, it
will use the funding received for research into new epigenetic anti-cancer
compounds, which we hope will give us promising starting points for
innovative drugs. However, our primary goal is still to secure the further
clinical development of resminostat so as to continue to work towards
market approval of our lead product."

Detailed financial review (9 months 2014 and Q3 2014):

The 4SC Group, which comprises 4SC AG and its wholly-owned subsidiary 4SC
Discovery GmbH, reports consolidated figures for the Group in accordance
with International Financial Reporting Standards (IFRSs) and financial
figures for the two operating segments Development (resminostat, 4SC-202
and 4SC-205) and Discovery & Collaborative Business (drug discovery and
early-stage research activities as well as their commercialisation through
the service business and research collaborations). The figures for the 4SC
Group are reported below; for more information on segment reporting, see
the full 9-month financial report at
(4sc.de/de/investors/financial-reports).

9 months 2014:

In the first nine months of 2014, consolidated revenue increased by 66%
year on year to EUR 6.18 million (9M 2013: EUR 3.72 million). This
primarily comprises revenue generated under the cooperation agreements with
BioNTech AG and LEO Pharma. 4SC also generated revenue of EUR 3.55 million
in the reporting period with its partner Yakult Honsha Co., Ltd. (9M 2013:
EUR 1.38 million). The Development segment saw revenue jump considerably by
75% to EUR 1.63 million (9M 2013: EUR 0.93 million). Revenue in the
Discovery & Collaborative Business segment rose by 12% to EUR 2.63 million
(9M 2013: EUR 2.35 million).

The loss from operations (EBIT) improved by 25% to EUR 6.21 million in the
reporting period (9M 2013: EUR 8.25 million) due to higher revenue. The
loss for the period decreased by 23% to EUR 6.31 million (9M 2013: EUR 8.19
million), which corresponds to earnings per share of EUR -0.12 (9M 2013: